← All trials
NCT04048161
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2019
- Primary completion
- Sep 30, 2022
- Completion date
- Dec 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 270
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang UniversityLead sponsor
- Peking UniversityCollaborator
- Fudan UniversityCollaborator
- Zhejiang UniversityStudy chair
- Zhejiang UniversityReponsible party - principal investigator
- Central South UniversityCollaborator
- Zhongshan Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- University of Electronic Science and Technology of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.